http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Byeong Kwan Park,HongKi Gwak,Seung Taek Lim,Young Jin Suh,Ye Won Jeon 한국유방암학회 2019 Journal of Breast Disease Vol.7 No.2
Purpose: The concurrent regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) has been categorized as a high-risk factor for febrile neutropenia (FN). The incidence of FN was reported to be as high as 17%–26% in studies conducted in Western countries. However, these rates may vary among different ethnic groups. This study aimed to evaluate the incidence of FN and its effect on prognosis following adjuvant TAC chemotherapy in Korean patients with advanced breast cancer. Methods: We analyzed data from 187 patients who received 6 cycles of adjuvant TAC chemotherapy between July 2005 and December 2014. No patients received long-acting granulocyte-colony stimulating factor (G-CSF) as primary prophylaxis for FN due to guidelines for cost reimbursement in Korea. The incidence rates of FN, dose reduction of TAC, relative dose intensity (RDI), relapse-free survival (RFS), and overall survival (OS) were investigated. Results: A total of 102 (54.5%) patients experienced FN, especially older patients (51 years vs. 49 years, p=0.045). RDI was lower in patients with FN than in those without (96.4% vs. 99.5%, p=0.001, respectively). Death was reported in 2 patients (2.35%) without FN and in 10 patients (9.80%) with FN (hazard ratio [HR]: 6.64; 95% confidence interval [CI]: 1.28 to 34.36; p=0.024). No significant differences in RFS (p=0.235) were found using Kaplan-Meier analysis. Conclusion: The incidence of FN was significantly higher in Korea than in Western countries, and FN had a negative impact on the patients’ prognosis. Primary prophylactic G-CSF should be prioritized in Korean patients with advanced breast cancer who receive adjuvant TAC chemotherapy.
Optimal hole extraction performance in MoOx-incorporated PEDOT:PSS films for organic photovoltaics
Hwang Tae-Ha,Gwak Donghoon,Cho Joonghyun,Bae Inho,Choi Jin Woo,Oh Dong Gun,Yang Si Hyeok,Kim Hongki,Kim Chang-Hyun 한국물리학회 2024 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.84 No.5
We propose a hole extraction system based on the metal-like poly(3,4-ethylenedioxythiophene):poly(styrene sulfonate) (PEDOT:PSS) blended with MoOx. Tuning the volume ratio of MoOx to PEDOT:PSS, the conductivity increases ten times, compared to that of pristine PEDOT:PSS flm. The efcient charge recombination and generation characteristics between MoOx with PEDOT:PSS are argued as the increase. No additional absorption peak due to the charge transfer in the hole transport layer implies that the system does not follow the P-type doping technique. The use of MoOx-mixed PEDOT:PSS thin flm as the hole extraction layer for the poly{4,8-bis[5-(2-ethylhexyl)-thiophen-2-yl]benzo[1,2-b;4,5-b’]dithiophene-2,6- diyl-alt-[4-(2-ethylhexyl)-3-fuorothieno[3,4-b]thiophene]-2-carboxylate-2-6-diyl} (PTB7-Th) and [6,6]-phenyl C70-butyric acid methyl ester (PC[70]BM)-based organic solar cells is found to increase the short circuit current density and fll factor of the device concomitant, and the power conversion efciency increases from 6.7 to 8.1% when the MoOx mixing ratio is 3%. The improved hole extraction performance of MoOx-mixed PEDOT:PSS thin flm would be benefcial for potential applications in organic electronic devices.
Ye Won Jeon,Seung Taek Lim,Hongki Gwak,Seon Young Park,Juhee Shin,Hye Sug Han,Young Jin Suh 대한외과학회 2021 Annals of Surgical Treatment and Research(ASRT) Vol.100 No.2
Purpose: Treatment with 4 cycles of docetaxel and cyclophosphamide (TC) in the adjuvant setting is associated with better outcomes than treatment with doxorubicin and cyclophosphamide (AC). However, Western guidelines have indicated that TC confers a high risk (>20%) of febrile neutropenia (FN), while AC confers an intermediate risk (10%-20%) of FN. Threrefore, we evaluated the incidence of FN and the clinical utilization of pegfilgrastim prophylaxis after adjuvant TC chemotherapy. Methods: We categorized 201 patients who received adjuvant TC chemotherapy into 3 groups according to the method of prophylaxis and compared neutropenic events, other adverse events, and hospital care costs in the 3 groups. Results: The incidence of grade 4 neutropenia decreased from 93.0% in patients without prophylaxis to 82.4% in those who received secondary prophylaxis and 16.7% in those who received primary prophylaxis. Although the incidence of FN was not different between patients without prophylaxis and patients who received secondary prophylaxis (15.7% and 14.9%), none of the patients who received primary prophylaxis developed FN. Moreover, a decrease in neutropenic events resulted in a significant decrease in the mean duration of neutropenia (2.50 days to 0.08 days, P < 0.001), the risk of hospitalization (29.8% to 2.2%, P < 0.001), and the mean total hospital care cost for all chemotherapy cycles (790.80 to 486.00 US dollars, P < 0.001). Conclusion: The use of pegfilgrastim prophylaxis during adjuvant TC chemotherapy is associated with significant decreases in the incidence of neutropenic events, hospitalization, and hospital care cost compared to those seen in patients without prophylaxis.